- Monoclonal Antibodies
- Tyrosine Kinase Inhibitors
- Thalidomide
- mTOR Inhibitors
- Others
Graft Versus Host Disease Treatment Market size was valued at USD 2,967.9 million in 2022, growing at a CAGR of 8.1% during the forecast period 2023 to 2029. By drug class, the global Graft vs Host Disease Treatment market has been segmented into Monoclonal Antibodies, Immunosuppressive Drugs, Steroids, TNF inhibitors, Tyrosine Kinase Inhibitors, and Others. The monoclonal antibodies segment is likely to be the largest and fastest-growing segment in terms of drug class. Based on Disease Type, the global Graft vs Host Disease Treatment market is segmented into Acute Graft vs Host Disease and chronic Graft vs Host Disease. Among these, the Acute Graft vs Host Disease segment is expected to be the fastest-growing segment during the forecast period. Based on route of administration, the global Graft vs Host Disease Treatment market is segmented into Oral and parenteral. The oral segment accounts for the largest share in 2021. Based on the distribution channel, the segment has been segregated into Hospital Pharmacies, Retail Pharmacies Online Pharmacies. The hospital pharmacies segment is expected to dominate other segments in the global market. The retail pharmacies segment is expected to witness the highest CAGR during the forecast period according to precision business insights.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Rising count of the allogeneic hematopoietic stem cell transplant and increase in the prevalence of cancer patients are majorly driving the growth of graft versus host disease treatment market. The increasing bone marrow transplantations for various types of cancers is likely to drive the growth of the market. The growing R&D activities is helping in fastening up the drug development process which is expected to add fuel for the growth of the market. However, the higher investment in the initial stages of the clinical trials is likely to hamper the growth of the market. The strict government regulations for approvals is also hindering the growth of the graft versus host disease treatment market.
The Graft Versus Host Disease Treatment Market size was valued at USD 2,967.9 million in 2022
The Graft Versus Host Disease Treatment Market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
Asia Pacific is the fastest-growing for Graft Versus Host Disease Treatment Market
1. Executive Summary |
2. Global Graft vs Host Disease Treatment Market Introduction |
2.1. Global Graft vs Host Disease Treatment Market-Taxonomy |
2.2. Global Graft vs Host Disease Treatment Market-Definitions |
2.2.1. By Drug Class |
2.2.2. By Disease Type |
2.2.3. By Route of Administration |
2.2.4. By Distribution Channel |
2.2.5. By Region |
3. Global Graft vs Host Disease Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Global Graft vs Host Disease Treatment Market Dynamic Factors - Impact Analysis |
3.6. Global Graft vs Host Disease Treatment Market Competition Landscape |
4. Global Graft vs Host Disease Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Graft vs Host Disease Treatment Market, By Drug Class, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.1. Monoclonal Antibodies |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Immunosuppressive Drugs |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Steroids |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. TNF Inhibitors |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Tyrosine Kinase Inhibitors |
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Others |
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
6. Global Graft vs Host Disease Treatment Market, By Disease Type, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.1. Acute Graft vs Host Disease |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Chronic Graft vs Host Disease |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
7. Global Graft vs Host Disease Treatment Market, By Route of Administration, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.1. Oral |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Parenteral |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
8. Global Graft vs Host Disease Treatment Market, By Distribution Channel, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.1. Hospital Pharmacies |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Retail Pharmacies |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Online Pharmacies |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
9. Global Graft vs Host Disease Treatment Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
9.1. North America |
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.2. Europe |
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.3. Asia-Pacific |
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
9.4. Latin America |
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.4.3. Market Opportunity Analysis |
9.5. Middle East and Africa |
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.5.3. Market Opportunity Analysis |
9.6. Global Graft vs Host Disease Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Region, 2024 - 2030 |
10. North America Graft vs Host Disease Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
10.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Monoclonal Antibodies |
10.1.2. Immunosuppressive Drugs |
10.1.3. Steroids |
10.1.4. TNF Inhibitors |
10.1.5. Tyrosine Kinase Inhibitors |
10.1.6. Others |
10.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.2.1. Acute Graft vs Host Disease |
10.2.2. Chronic Graft vs Host Disease |
10.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
10.3.1. Oral |
10.3.2. Parenteral |
10.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
10.4.1. Hospital Pharmacies |
10.4.2. Retail Pharmacies |
10.4.3. Online Pharmacies |
10.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
10.5.1. USA |
10.5.2. Canada |
10.6. North America Graft vs Host Disease Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Country, 2024 - 2030 |
10.7. North America Graft vs Host Disease Treatment Market Dynamics Trends |
11. Europe Graft vs Host Disease Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
11.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Monoclonal Antibodies |
11.1.2. Immunosuppressive Drugs |
11.1.3. Steroids |
11.1.4. TNF Inhibitors |
11.1.5. Tyrosine Kinase Inhibitors |
11.1.6. Others |
11.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.2.1. Acute Graft vs Host Disease |
11.2.2. Chronic Graft vs Host Disease |
11.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.3.1. Oral |
11.3.2. Parenteral |
11.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.4.1. Hospital Pharmacies |
11.4.2. Retail Pharmacies |
11.4.3. Online Pharmacies |
11.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
11.5.1. Germany |
11.5.2. UK |
11.5.3. France |
11.5.4. Spain |
11.5.5. Italy |
11.5.6. Russia |
11.5.7. Rest of Europe |
11.6. Europe Graft vs Host Disease Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Country, 2024 - 2030 |
11.7. Europe Graft vs Host Disease Treatment Market Dynamics Trends |
12. Asia-Pacific Graft vs Host Disease Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
12.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Monoclonal Antibodies |
12.1.2. Immunosuppressive Drugs |
12.1.3. Steroids |
12.1.4. TNF Inhibitors |
12.1.5. Tyrosine Kinase Inhibitors |
12.1.6. Others |
12.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.2.1. Acute Graft vs Host Disease |
12.2.2. Chronic Graft vs Host Disease |
12.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.3.1. Oral |
12.3.2. Parenteral |
12.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.4.1. Hospital Pharmacies |
12.4.2. Retail Pharmacies |
12.4.3. Online Pharmacies |
12.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
12.5.1. China |
12.5.2. India |
12.5.3. Japan |
12.5.4. ASEAN |
12.5.5. Australia & New Zealand |
12.5.6. Rest of Asia-Pacific |
12.6. Asia-Pacific Graft vs Host Disease Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Country, 2024 - 2030 |
12.7. Asia-Pacific Graft vs Host Disease Treatment Market Dynamics Trends |
13. Latin America Graft vs Host Disease Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
13.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
13.1.1. Monoclonal Antibodies |
13.1.2. Immunosuppressive Drugs |
13.1.3. Steroids |
13.1.4. TNF Inhibitors |
13.1.5. Tyrosine Kinase Inhibitors |
13.1.6. Others |
13.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
13.2.1. Acute Graft vs Host Disease |
13.2.2. Chronic Graft vs Host Disease |
13.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
13.3.1. Oral |
13.3.2. Parenteral |
13.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
13.4.1. Hospital Pharmacies |
13.4.2. Retail Pharmacies |
13.4.3. Online Pharmacies |
13.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
13.5.1. Brazil |
13.5.2. Mexico |
13.5.3. Rest of Latin America |
13.6. Latin America Graft vs Host Disease Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Country, 2024 - 2030 |
13.7. Latin America Graft vs Host Disease Treatment Market Dynamics Trends |
14. Middle East and Africa Graft vs Host Disease Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
14.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
14.1.1. Monoclonal Antibodies |
14.1.2. Immunosuppressive Drugs |
14.1.3. Steroids |
14.1.4. TNF Inhibitors |
14.1.5. Tyrosine Kinase Inhibitors |
14.1.6. Others |
14.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
14.2.1. Acute Graft vs Host Disease |
14.2.2. Chronic Graft vs Host Disease |
14.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
14.3.1. Oral |
14.3.2. Parenteral |
14.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
14.4.1. Hospital Pharmacies |
14.4.2. Retail Pharmacies |
14.4.3. Online Pharmacies |
14.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
14.5.1. Gulf Cooperation Council (GCC) Countries |
14.5.2. South Africa |
14.5.3. Rest of MEA |
14.6. MEA Graft vs Host Disease Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Country, 2024 - 2030 |
14.7. MEA Graft vs Host Disease Treatment Market Dynamics Trends |
15. Competition Landscape |
15.1. Strategic Dashboard of Top Market Players |
15.2. Company Profiles (Introduction, Financial Analysis, Key Offerings, Key Developments, Strategies, and SWOT Analysis) |
15.2.1. F. Hoffmann-La Roche Ltd. |
15.2.2. AbbVie, Inc. |
15.2.3. Bristol-Myers Squibb |
15.2.4. Pfizer, Inc. |
15.2.5. Baxter International plc |
15.2.6. Novartis AG |
15.2.7. Eli Lilly and Co. |
15.2.8. Shire plc |
15.2.9. Alleran plc |
15.2.10. Caladrius |
15.2.11. Eisai |
15.2.12. Anterogen |
16. Research Methodology |
17. Key Assumptions and Acronyms |